Now Available: Final Rule for FDAAA 801 and NIH Policy on Clinical Trial Reporting

Head and Neck Cancer Registry (LORHAN) (LORHAN)

This study has been completed.
Information provided by (Responsible Party):
Eli Lilly and Company Identifier:
First received: March 2, 2010
Last updated: February 10, 2012
Last verified: February 2012
The primary objective of this study is to describe, in detail, patterns of care for head and neck carcinoma patient

Condition Intervention
Head and Neck Cancer
Other: Therapy for head and neck cancer

Study Type: Observational
Study Design: Time Perspective: Prospective
Official Title: Prospective, Longitudinal, Multi-Center, Descriptive Registry of Patients Receiving Therapy Other Than Surgical Resection Alone for Newly Diagnosed Head and Neck Cancer

Resource links provided by NLM:

Further study details as provided by Eli Lilly and Company:

Primary Outcome Measures:
  • Patterns of care for head and neck cancer [ Time Frame: up to 10 years ] [ Designated as safety issue: No ]

Secondary Outcome Measures:
  • Overall survival by treatment regimen [ Time Frame: study entry to death from any cause or to end of study ] [ Designated as safety issue: No ]
  • Determine the incidence and severity of major dose-limiting and other important treatment toxicities [ Time Frame: up to 10 years ] [ Designated as safety issue: Yes ]
  • Identify supportive care received for managing nutrition, pain, nausea and other complications [ Time Frame: up to 10 years ] [ Designated as safety issue: No ]
  • tumor control by treatment regimen [ Time Frame: study entry to progressive disease ] [ Designated as safety issue: No ]

Estimated Enrollment: 26000
Study Start Date: August 2005
Study Completion Date: December 2011
Primary Completion Date: December 2011 (Final data collection date for primary outcome measure)
Groups/Cohorts Assigned Interventions
Patients with head and neck cancer Other: Therapy for head and neck cancer
radiotherapy and/or drug therapy including chemotherapy, biologic therapy and targeted therapy


Ages Eligible for Study:   18 Years and older   (Adult, Senior)
Genders Eligible for Study:   All
Accepts Healthy Volunteers:   No
Sampling Method:   Non-Probability Sample
Study Population
Primary care clinic

Inclusion Criteria:

  • Pathologically (histologically or cytologically) confirmed new diagnosis of carcinoma involving the oral cavity, oropharynx, nasopharynx, hypopharynx, larynx, or neck node metastasis from unknown origin
  • Scheduled to receive radiotherapy and/or drug therapy including chemotherapy, biologic therapy and targeted therapy
  • Written informed consent

Exclusion Criteria:

  • Registry participation does not exclude participation in clinical trials.
  • Patients scheduled to receive or who have received surgery are eligible for Registry participation as long as they are also scheduled to receive medical therapy.
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT01080313

United States, Minnesota
Mednet Solutions
Minnetonka, Minnesota, United States, 55305
Sponsors and Collaborators
Eli Lilly and Company
Study Director: Mednet Solutions Mednet Solutions
  More Information

Responsible Party: Eli Lilly and Company Identifier: NCT01080313     History of Changes
Other Study ID Numbers: 13440  I4E-US-S003 
Study First Received: March 2, 2010
Last Updated: February 10, 2012
Health Authority: United States: Food and Drug Administration

Additional relevant MeSH terms:
Head and Neck Neoplasms
Neoplasms by Site
Neoplasms processed this record on January 17, 2017